Skip to content
BHP

Orforglipron half-life & pharmacokinetics

Reference

Reviewed by the BestHealingPeptides Editorial Team ·

Reported half-life

Elimination half-life of approximately 29 to 49 hours, enabling once-daily administration (UK SmPC section 5.2). The maximum concentration is reached 4 to 8 hours after a dose, and steady-state exposure is achieved after approximately 1 week of once-daily dosing. Orforglipron is highly bound (99.9%) in human plasma (SmPC section 5.2).

The half-life figure above is the elimination half-life of approximately 29 to 49 hours stated in section 5.2 of the UK Summary of Product Characteristics. It underlies the once-daily dosing of Foundayo. Plasma half-life describes the time taken for the circulating concentration to fall by half and is not a guide to changing a prescribed regimen.

Licensed routes of administration

  • Oral film-coated tablet (once daily; licensed route)

Drug class

Oral non-peptide GLP-1 receptor agonist; UK prescription only medicine (Foundayo) for weight management and type 2 diabetes; ATC code not yet assigned in the UK SmPC.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Orforglipron acts as follows:

Orforglipron (Eli Lilly development code LY3502970) is described in section 5.1 of the UK SmPC as an oral high-affinity nonpeptide GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. It is a small molecule rather than a peptide: PubChem gives its molecular formula as C48H48F2N10O5 and its molecular weight as 883.0. The UK SmPC states that each film-coated tablet contains orforglipron calcium.

See the full Orforglipron research profile for the complete mechanism summary, history, study citations, and references.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.